仁度生物(688193) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 162.06 million, a decrease of 8.62% compared to RMB 177.35 million in the previous year[5] - Net profit attributable to the parent company was RMB 9.51 million, an increase of RMB 17.32 million year-on-year[8] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB -12.28 million, an increase of RMB 7.28 million compared to the previous year[8] - Basic earnings per share increased to RMB 0.24 from a loss of RMB 0.20 in the previous year[5] Assets and Equity - Total assets at the end of the reporting period were RMB 989.51 million, a decrease of 0.49% from the beginning of the period[8] - Equity attributable to the parent company increased by 0.16% to RMB 913.33 million[8] Operational Improvements - The company implemented cost reduction and efficiency improvement measures, leading to a decrease in period expenses[8] - The company improved accounts receivable management, recovering some receivables from previous years[8] Return on Investment - The weighted average return on net assets increased by 1.87 percentage points to 1.04%[5] Audit and Reporting - The financial data presented is preliminary and subject to final audit in the annual report[11]